Refractory intracranial hypertension in posterior reversible encephalopathy syndrome

Alberto Facchini, Sandra Magnoni, Vittorio Civelli, Fabio Triulzi, Mario Nosotti, Nino Stocchetti

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Introduction: Posterior reversible encephalopathy syndrome (PRES) is a largely reversible disease with long-term favorable outcome. A minority of patients, however, may develop progressive cerebral edema and ischemia resulting in severe disability or death. We report a case of severe intracranial hypertension associated with PRES that was successfully treated according to intracranial pressure (ICP)- and cerebral perfusion pressure (CPP)-driven therapy. Methods: Case report. Results: A 42-year-old woman underwent bilateral lung transplantation for severe bronchiectasis. Her immunosuppressive regimen consisted of azathioprine, prednisone, and tacrolimus. She acutely developed an aggressive form of PRES that rapidly resulted in severe refractory intracranial hypertension despite discontinuation of potentially causative medications and adequate supportive therapy. Accordingly, second-tier therapies, including barbiturate infusion, were instituted and immunosuppression was switched to anti-thymocyte globulin followed by mycophenolate mofetil. Within 10 h of barbiturate administration, ICP dropped to 20 mmHg. Thiopental was administered for two days and then rapidly tapered because of severe urosepsis. Six months after discharge from the intensive care unit the patient returned to near-normal life, her only complaint being short-term amnesia. Conclusions: The decision to undertake ICP monitoring in medical conditions in which no clear recommendations exist greatly relies on physicians' judgment. This case suggests that ICP monitoring may be considered in the setting of acute PRES among selected patients, when severe intracranial hypertension is suspected, provided that a multidisciplinary team of neurocritical care specialists is readily available.

Original languageEnglish
Pages (from-to)376-380
Number of pages5
JournalNeurocritical Care
Volume19
Issue number3
DOIs
Publication statusPublished - Dec 2013

Fingerprint

Posterior Leukoencephalopathy Syndrome
Intracranial Hypertension
Intracranial Pressure
Cerebrovascular Circulation
Mycophenolic Acid
Bronchiectasis
Antilymphocyte Serum
Amnesia
Thiopental
Lung Transplantation
Brain Edema
Azathioprine
Tacrolimus
Immunosuppressive Agents
Prednisone
Brain Ischemia
Immunosuppression
Intensive Care Units
Therapeutics
Physicians

Keywords

  • Barbiturate
  • Immunosuppressive agents
  • Intracranial hypertension
  • Lung transplantation
  • Reversible posterior leukoencephalopathy syndrome
  • Status epilepticus

ASJC Scopus subject areas

  • Clinical Neurology
  • Critical Care and Intensive Care Medicine

Cite this

Refractory intracranial hypertension in posterior reversible encephalopathy syndrome. / Facchini, Alberto; Magnoni, Sandra; Civelli, Vittorio; Triulzi, Fabio; Nosotti, Mario; Stocchetti, Nino.

In: Neurocritical Care, Vol. 19, No. 3, 12.2013, p. 376-380.

Research output: Contribution to journalArticle

@article{b1b5d5af341b4d8888d01dcbf9ed6666,
title = "Refractory intracranial hypertension in posterior reversible encephalopathy syndrome",
abstract = "Introduction: Posterior reversible encephalopathy syndrome (PRES) is a largely reversible disease with long-term favorable outcome. A minority of patients, however, may develop progressive cerebral edema and ischemia resulting in severe disability or death. We report a case of severe intracranial hypertension associated with PRES that was successfully treated according to intracranial pressure (ICP)- and cerebral perfusion pressure (CPP)-driven therapy. Methods: Case report. Results: A 42-year-old woman underwent bilateral lung transplantation for severe bronchiectasis. Her immunosuppressive regimen consisted of azathioprine, prednisone, and tacrolimus. She acutely developed an aggressive form of PRES that rapidly resulted in severe refractory intracranial hypertension despite discontinuation of potentially causative medications and adequate supportive therapy. Accordingly, second-tier therapies, including barbiturate infusion, were instituted and immunosuppression was switched to anti-thymocyte globulin followed by mycophenolate mofetil. Within 10 h of barbiturate administration, ICP dropped to 20 mmHg. Thiopental was administered for two days and then rapidly tapered because of severe urosepsis. Six months after discharge from the intensive care unit the patient returned to near-normal life, her only complaint being short-term amnesia. Conclusions: The decision to undertake ICP monitoring in medical conditions in which no clear recommendations exist greatly relies on physicians' judgment. This case suggests that ICP monitoring may be considered in the setting of acute PRES among selected patients, when severe intracranial hypertension is suspected, provided that a multidisciplinary team of neurocritical care specialists is readily available.",
keywords = "Barbiturate, Immunosuppressive agents, Intracranial hypertension, Lung transplantation, Reversible posterior leukoencephalopathy syndrome, Status epilepticus",
author = "Alberto Facchini and Sandra Magnoni and Vittorio Civelli and Fabio Triulzi and Mario Nosotti and Nino Stocchetti",
year = "2013",
month = "12",
doi = "10.1007/s12028-013-9852-z",
language = "English",
volume = "19",
pages = "376--380",
journal = "Neurocritical Care",
issn = "1541-6933",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Refractory intracranial hypertension in posterior reversible encephalopathy syndrome

AU - Facchini, Alberto

AU - Magnoni, Sandra

AU - Civelli, Vittorio

AU - Triulzi, Fabio

AU - Nosotti, Mario

AU - Stocchetti, Nino

PY - 2013/12

Y1 - 2013/12

N2 - Introduction: Posterior reversible encephalopathy syndrome (PRES) is a largely reversible disease with long-term favorable outcome. A minority of patients, however, may develop progressive cerebral edema and ischemia resulting in severe disability or death. We report a case of severe intracranial hypertension associated with PRES that was successfully treated according to intracranial pressure (ICP)- and cerebral perfusion pressure (CPP)-driven therapy. Methods: Case report. Results: A 42-year-old woman underwent bilateral lung transplantation for severe bronchiectasis. Her immunosuppressive regimen consisted of azathioprine, prednisone, and tacrolimus. She acutely developed an aggressive form of PRES that rapidly resulted in severe refractory intracranial hypertension despite discontinuation of potentially causative medications and adequate supportive therapy. Accordingly, second-tier therapies, including barbiturate infusion, were instituted and immunosuppression was switched to anti-thymocyte globulin followed by mycophenolate mofetil. Within 10 h of barbiturate administration, ICP dropped to 20 mmHg. Thiopental was administered for two days and then rapidly tapered because of severe urosepsis. Six months after discharge from the intensive care unit the patient returned to near-normal life, her only complaint being short-term amnesia. Conclusions: The decision to undertake ICP monitoring in medical conditions in which no clear recommendations exist greatly relies on physicians' judgment. This case suggests that ICP monitoring may be considered in the setting of acute PRES among selected patients, when severe intracranial hypertension is suspected, provided that a multidisciplinary team of neurocritical care specialists is readily available.

AB - Introduction: Posterior reversible encephalopathy syndrome (PRES) is a largely reversible disease with long-term favorable outcome. A minority of patients, however, may develop progressive cerebral edema and ischemia resulting in severe disability or death. We report a case of severe intracranial hypertension associated with PRES that was successfully treated according to intracranial pressure (ICP)- and cerebral perfusion pressure (CPP)-driven therapy. Methods: Case report. Results: A 42-year-old woman underwent bilateral lung transplantation for severe bronchiectasis. Her immunosuppressive regimen consisted of azathioprine, prednisone, and tacrolimus. She acutely developed an aggressive form of PRES that rapidly resulted in severe refractory intracranial hypertension despite discontinuation of potentially causative medications and adequate supportive therapy. Accordingly, second-tier therapies, including barbiturate infusion, were instituted and immunosuppression was switched to anti-thymocyte globulin followed by mycophenolate mofetil. Within 10 h of barbiturate administration, ICP dropped to 20 mmHg. Thiopental was administered for two days and then rapidly tapered because of severe urosepsis. Six months after discharge from the intensive care unit the patient returned to near-normal life, her only complaint being short-term amnesia. Conclusions: The decision to undertake ICP monitoring in medical conditions in which no clear recommendations exist greatly relies on physicians' judgment. This case suggests that ICP monitoring may be considered in the setting of acute PRES among selected patients, when severe intracranial hypertension is suspected, provided that a multidisciplinary team of neurocritical care specialists is readily available.

KW - Barbiturate

KW - Immunosuppressive agents

KW - Intracranial hypertension

KW - Lung transplantation

KW - Reversible posterior leukoencephalopathy syndrome

KW - Status epilepticus

UR - http://www.scopus.com/inward/record.url?scp=84890460152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890460152&partnerID=8YFLogxK

U2 - 10.1007/s12028-013-9852-z

DO - 10.1007/s12028-013-9852-z

M3 - Article

VL - 19

SP - 376

EP - 380

JO - Neurocritical Care

JF - Neurocritical Care

SN - 1541-6933

IS - 3

ER -